Episode 1: NVAF in a Patient With a History of Stroke and Bleeding

Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708.
Alkhouli M, Noseworthy PA, Rihal CS, et al. Stroke prevention in nonvalvular atrial fibrillation: a stakeholder perspective. J Am Coll Cardiol. 2018;71:2790-2801.
Braunwald E. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360-1369.
Christiansen CB, Gerds TA, Olesen JB, et al. Atrial fibrillation and risk of stroke: a nationwide cohort study. Europace. 2016;18:1689-1697.
Cheung KS, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J Gastroenterol. 2017 Mar 21;23:1954-1963.
Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847.
Connolly SJ, Ezekowitz MD, Yusuf S, et al for the RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
Connolly SJ, Ezekowitz MD, Yusuf S, et al for the Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875-1876.
De Caterina R, Andersson U, Alexander JH, et al for the ARISTOTLE Investigators. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Am Heart J. 2016;175:175-183
Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation. 2012;125:2298-2307.
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.
Guo WQ, Chen XH, Tian XY, et al. Differences in gastrointestinal safety profiles among novel oral anticoagulants: evidence from a network meta-analysis. Clin Epidemiol. 2019;11:911-921.
Huisman MV, Rothman KJ, Paquette M, et al for the GLORIA-AF Investigators. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF Registry Phase 2. J Am Coll Cardiol. 2017;69:777-785.
Hylek EM, Held C, Alexander JH, et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014;63:2141-2147.
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140:e125-e151.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18:1609-1678.
Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2020.
DOI: 10.1177/1747493019897870 [Epub ahead of print]
Morillo CA, Banerjee A, Perel P, et al. Atrial fibrillation: the current epidemic. J Geriatr Cardiol. 2017;14:195-203.
Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke. 2017;12:589-596.
Olesen JB, Sorensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011–2013. Europace. 2015;17:187-193.
Otite FO, Khandelwal P, Chaturvedi S, et al. Increasing atrial fibrillation prevalence in acute ischemic stroke and TIA. Neurology. 2016;87:2034-2042.
Patel MR, Mahaffey KW, Garg J, et al for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
Piccini JP, Garg J, Patel MR, et al, for the ROCKET AF Investigators. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J. 2014;35:1873-1880.
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-100.
Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725.
Zhu W, He W, Guo L, et al. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2015;38:555-561.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Sana Al-Khatib, MD, MHS

Professor of Medicine
Duke University Medical Center
Durham, North Carolina

Disclosures

Disclosure: Sana Al-Khatib, MD, MS, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Medtronic; Milestone Pharmaceuticals
Served as a speaker or a member of a speakers bureau for: Bristol Myers Squibb; Medtronic; Pfizer

Editors

Lih-Fan Chang, MD, MPH

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Lih-Fan Chang, MD, MPH, has disclosed no relevant financial relationships.

Philippa M. Berman, BA (Hons), MBBS

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Philippa M. Berman, BA (Hons), MBBS, has disclosed no relevant financial relationships.

Kevan H. Chambers, CBiol, MRSB

Medical Writer, WebMD Global, LLC

Disclosures

Disclosure: Kevan H. Chambers, CBiol, MRSB, has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance , Medscape, LLC

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

processing....

Legendas em português

« Return to: Episode 1: NVAF in a Patient With a History of Stroke and Bleeding

Activity Transcript

References

Faculty and Disclosures

Faculty

Sana Al-Khatib, MD, MHS

Editors

Lih-Fan Chang, MD, MPH

Philippa M. Berman, BA (Hons), MBBS

Kevan H. Chambers, CBiol, MRSB

Content Reviewer

Robert Morris, PharmD

Episode 1: NVAF in a Patient With a History of Stroke and Bleeding

Legendas em português